Sponsored by
Multiple sites across several states are now enrolling patients for a Phase II trial testing a personalized dendritic cell therapy for glioblastoma (GBM). This therapy, called DOC1021 or Dubodencel, uses a sample of the patient’s own tumor to teach their dendritic cells what the cancer looks like, so the immune system can recognize and attack it. The therapy is described as "double-loaded" because it utilizes both tumor lysate and amplified tumor mRNA. In the earlier Phase I trial of 16 newly diagnosed GBM patients (15 of whom were unmethylated), the treatment showed a favorable safety profile and a 12 month survival rate of 88%. Notably, four patients remained alive at 22 to 33 months of follow-up.